FASENRA
FASENRA (benralizumab) is a monoclonal antibody that helps the body’s immune system by reducing the level of a certain type of white blood cells, helping to protect healthy cells from damage. Specifically, it is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody (IgG1 kappa) used as an add-on maintenance treatment of patients with severe asthma aged 12 years and older with an eosinophilic phenotype.
For more information, visit the patient website for this drug. Speak with your healthcare provider to learn if this drug is right for you.
What it treats
Severe eosinophilic asthma
Prescribed by
Pulmonologists
How it’s administered
Subcutaneous injection
Frequency
Every four weeks for three doses,
and then every eight weeks
Length of treatment
About 15 minutes, plus 30-minute observation